Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note issued to investors on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Performance

NASDAQ:GLMD opened at $1.78 on Wednesday. The stock’s fifty day moving average price is $2.61 and its two-hundred day moving average price is $3.47. Galmed Pharmaceuticals has a 52-week low of $1.75 and a 52-week high of $23.80. The company has a market cap of $1.15 million, a price-to-earnings ratio of -0.11 and a beta of 0.72.

Institutional Trading of Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.